Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Mongiardi, Maria Patrizia ^a   Savino, Mauro ^b,c,f   Bartoli, Laura ^b,c   Beji, Sara ^b,c,g   Nanni, Simona ^d   Scagnoli, Fiorella ^b,c   Falchetti, Maria Laura ^a   Favia, Annarita ^b,c   Farsetti, Antonella ^a,e   Levi, Andrea ^a   Nasi, Sergio ^b,c   Illi, Barbara ^b  

^a CNR   (Italy)

^b National Research Council (IBPM CNR)   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f Diatech Pharmacogenetics   (Italy)

^g LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CHROMATIN; HISTONE; MEP50 PROTEIN, HUMAN; MYC PROTEIN; OMOMYC PROTEIN; PEPTIDE FRAGMENT; PRMT5 PROTEIN, HUMAN; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN BINDING; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

CHROMATIN; CONFOCAL MICROSCOPY; GENETICS; GLIOBLASTOMA; HEK293 CELL LINE; HUMAN; METABOLISM; METHYLATION; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ARGININE; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMATIN; GLIOBLASTOMA; HEK293 CELLS; HISTONES; HUMANS; METHYLATION; MICROSCOPY, CONFOCAL; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN-ARGININE N-METHYLTRANSFERASES; PROTO-ONCOGENE PROTEINS C-MYC; RNA INTERFERENCE;

EID: 84946914665     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15494     Document Type: Article

References (52)

1. Eilers, M. & Eisenman, R. N. Myc's broad reach. Genes Dev. 22, 2755-2766 (2008).
2. Rahl, P. B. et al. Myc regulates transcriptional pause release. Cell. 141, 432-445 (2010).
3. Nie, Z. et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 151, 68-79 (2012).
4. Lin, C. Y. et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 151, 56-67 (2012).
5. Kaur, M. & Cole, M. D. MYC acts via the PTEN tumor suppressor to elicit autoregulation and genome-wide gene repression by activation of the Ezh2 methyltransferase.Cancer Res. 73, 695-705 (2013).
6. Kuser-Abali, G., Alptekin, A. & Cinar, B. Overexpression of MYC and EZH2 cooperates to epigenetically silence MST1 expression. Epigenetics. 9, 634-643 (2014).
7. Bandopadhayay, P. et al. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res. 20, 912-925 (2014).
8. Soucek, L. et al. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev. 27, 504-513 (2013).
9. Soucek, L. et al. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene. 17, 2463-2472 (1998).
10. Soucek, L. et al. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. Cancer Res. 62, 3507-3510 (2002).
11. Savino, M. et al. The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. PLoS One. 6, e22284 (2011).
12. Soucek, L. et al. Modelling Myc inhibition as a cancer therapy. Nature. 455, 679-683 (2008).
13. Sodir, N. M. et al. Endogenous Myc maintains the tumor microenvironment. Genes Dev. 25, 907-916 (2011).
14. Annibali, D. et al. Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis. Nat Commun. 5, 4632 (2014).
15. Preusser, M. et al. Current Concepts and Management of Glioblastoma. Ann Neurol. 70, 9-21 (2011).
16. Piccirillo, S. G. & Vescovi, A. L. Brain tumour stem cells: possibilities of new therapeutic strategies. Expert Opin Biol Ther. 7, 1129-35 (2007).
17. Kim, J. et al. Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell. 143, 313-324 (2010).
18. Wang, J. et al. c-Myc is required for maintenance of glioma cancer stem cells. PloS One. 3, e3769 (2008).
19. Feinberg, A. P. & Vogelstein, B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 301, 89-92 (1983).
20. Yost, J. M., Korboukh, I., Liu, F., Gao, C. & Jin, J. Targets in epigenetics, inhibiting the methyl writers of the histone code. Curr Chem Genomics. 5(Suppl 1), 72-84 (2011).
21. Wolf, S. S. The protein arginine methyltransferase family, An update about function, new perspectives and the physiological role in humans. Cell Mol Life Sci. 66, 2109-2121 (2009).
22. Migliori, V. et al. Symmetric dimethylation of H3R2 is a newly identified histone mark that supports euchromatin maintenance. Nat Struct Mol Biol. 19, 136-144 (2012).
23. Han, X. et al. Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro. J Neurooncol 118, 61-72 (2014).
24. Yan, F. et al. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. Cancer Re. 74, 1752-1765 (2014).
25. Friesen, W. J. et al. A novel WD repeat protein component of the methylosome binds Sm proteins. J Biol Chem. 277, 8243-8247 (2002).
26. Lacroix, M. et al. The histone-binding protein COPR5 is required for nuclear functions of the protein arginine methyltransferase PRMT5. EMBO Rep. 9, 452-458 (2008).
27. Pal, S. et al. mSin3A/histone deacetylase 2- and PRMT5-containing Brg1 complex is involved in transcriptional repression of the Myc target gene cad. Mol Cell Biol. 23, 7475-7487 (2003).
28. Daksis, J. I., Lu, R. Y., Facchini, L. M., Marhin, W. W. & Penn, L. J. Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulatedsignal transduction to the cell cycle.Oncogene. 9, 3635-3645 (1994).
29. Chittka, A., Nitarska, J., Grazini, U. & Richardson, W. D. Transcription factor positive regulatory domain 4 (PRDM4) recruits protein arginine methyltransferase 5 (PRMT5) to mediate histone arginine methylation and control neural stem cell proliferation and differentiation. J Biol Chem. 287, 42995-43006 (2012).
30. Dacwag, C. S., Ohkawa, Y., Pal, S., Sif, S. & Imbalzano, A. N. The protein arginine methyltransferase Prmt5 is required for myogenesis because it facilitates ATP-dependent chromatin remodeling. Mol Cell Biol. 27, 384-394 (2007).
31. Tsai, W. W. et al. PRMT5 modulates the metabolic response to fasting signals. Proc Natl Acad Sci USA. 110, 8870-8875 (2013).
32. Nagamatsu, G. et al. A germ cell-specific gene, Prmt5, works in somatic cell reprogramming. J Biol Chem. 286, 10641-10648 (2011).
33. Kim, S. et al. PRMT5 Protects Genomic Integrity during Global DNA Demethylation in Primordial Germ Cells and Preimplantation Embryos Mol Cell. 56, 564-579 (2014).
34. Zhou, Z. et al. PRMT5 regulates Golgi apparatus structure through methylation of the golgin GM130. Cell Res. 20, 1023-1033 (2010).
35. Ren, J. et al. Methylation of ribosomal protein S10 by protein arginine methyltransferase 5 regulates ribosome biogenesis. J Biol Chem. 285, 12695-12705 (2010).
36. Tee, W. W. et al. Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency. Genes Dev. 24, 2772-2777 (2010).
37. Guo, S. & Bao, S. srGAP2 arginine methylation regulates cell migration and cell spreading through promoting dimerization. J Biol Chem. 285, 35133-3541 (2010).
38. Karkhanis, V., Hu, Y. J., Baiocchi, R. A., Imbalzano, A. N. & Sif, S. Versatility of PRMT5-induced methylation in growth control and development. Trends Biochem Sci. 36, 633-641 (2011).
39. Ancelin, K. et al. Blimp1 associates with Prmt5 and directs histone arginine methylation in mouse germ cells. Nat Cell Biol. 8, 623-630 (2006).
40. Sankaran, V. G., Xu, J. & Orkin, S. H. Advances in the understanding of haemoglobin switching. Br J Haematol. 149, 181-194 (2010).
41. Park, J. H. et al. Protein arginine methyltransferase 5 is a key regulator of the MYCN oncoprotein in neuroblastoma cells. Mol Oncol. 9, 617-627 (2015).
42. LeBlanc, S. E. et al. Protein arginine methyltransferase 5 (Prmt5) promotes gene expression of peroxisome proliferator-activated receptor γ2 (PPARγ2) and its target genes during adipogenesis. Mol Endocrinol. 26, 583-597 (2012).
43. Zhao, Q. et al. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat Struct Mol Biol 16, 304-311 (2009).
44. Ullius, A. et al.The interaction of MYC with the trithorax protein ASH2L promotes gene transcription by regulating H3K27 modification. Nucleic Acids Res. 42, 6901-6920 (2014).
45. Takai, H. et al. 5 Hydroxymethylcytosine plays a critical role in glioblastomagenesis by recruiting the CHTOP-methylosome complex. Cell Rep. 9, 48-60 (2014).
46. Gu, Z. et al. Protein arginine methyltransferase 5 functions in opposite ways in the cytoplasm and nucleus of prostate cancer cells. PLoS One 7, e44033 (2012).
47. Nicholas, C. et al. PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1). PLoS One. 8, e74710 (2013).
48. Ibrahim, R. et al. Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition. Hum Pathol. 45, 1397-1405 (2014).
49. De Bacco, F. et al. The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res. 72, 4537-4550 (2012).
50. Rupp, R. A., Snider, L. & Weintraub, H. Xenopus embryos regulate the nuclear localization of XMyoD. Genes Dev. 8, 1311-1323 (1994).
51. Illi, B. et al. Nitric oxide modulates chromatin folding in human endothelial cells via protein phosphatase 2A activation and class II histone deacetylases nuclear shuttling Circ Res. 102, 51-58 (2008).
52. Nanni, S. et al. Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest. 119, 1093-10108 (2009).